“We continue to conduct and innovate relentlessly, as evidenced by the achievements of our full first quarter as a public company,” said David Kirn, MD, co-founder and CEO of 4DMT. knowledge of our 4D-310 candidate product for Fabry disease and our 4D-125 XLRP candidate product at this time of year. In addition, we are on track to publish clinical trials at this year for 4D-150, our AMD candidate product and wet DME, and 4D-710, our candidate product for cystic fibrosis lung disease. We also recently expanded our generation platform to include device learning applications, and yesterday, at the annual ASGCT conference, we presented preclinical knowledge about 4D-150 non-human primates. »
Recent operational highlights
Next expected milestones
Cash and money equivalents: Cash and money equivalents were $259. 9 million as of March 31, 2021. We expect money and money equivalents to be sufficient to finance operations by mid-2023.
Revenue: Total income of $2. 0 million for the 3 months ended March 31, 2021, compared to $3. 5 million for the 3 months ended March 31, 2020. Minimization is mainly due to the minimisation of profits under the Roche Partnership Agreement.
Research and progression expenses: Research and progression expenses were $12. 8 million for the 3 months ended March 31, 2021, compared to $13. 2 million of the 3 months ended March 31, 2020, which is basically minimized by minimizing external production costs, which partially offset through the higher payroll and stock-based repayment costs.
Overhead and administrative expenses: Overhead and administrative expenses were $5. 5 million for the 3 months ended March 31, 2021, compared to $3. 7 million for the 3 months ended March 31, 2020, which was basically due to higher payroll and share-based payment. and higher insurance costs.
About 4DMT
4DMT is a clinically staged company that harnesses the strength of targeted evolution for targeted gene therapies. 4DMT seeks to unlock the full perspective of gene treatment through its platform, Therapeutic Vector Evolution, which combines the strength of targeted evolution with around one billion artificial capsside sequences. to invent complex vectors to be used in targeted gene treatment products. The company focuses first on 3 healing areas: ophthalmology, cardiology and pneumology. Directed and evolved 4DMT vectors are invented for clinically common, well-tolerated and minimally invasive delivery pathways, transducing diseased cells well into target tissues with reduced immunogenicity and, if necessary, resistance to pre-existing antibodies. 4DMT is recently conducting 3 clinical trials: 4D-125 is in a phase 1/2 clinical trial for XLRP patients, 4D-110 is in phase 1 clinical trial for patients with coroideramia and 4D-310 is in phase 1/2 clinical trial for patients with Fabry disease.
4D Molecular Therapeutics ™, 4DMT ™, Therapeutic Vector Evolution ™ and the 4DMT logo are registered with 4DMT.
Caution related to forward-looking statements
The 4D-310, 4D-125 and 4D-110 are our candidate products in clinical trials and have still been approved for commercialization through the US FDA. But it’s not the first time Or any other regulatory authority. No statement is made as to the protection or efficacy of 4D-310, 4D-125 or 4D-110 for the curative use for which they are being studied.
4D Molecular Therapeutics, Inc. States of condensed income and comprehensive (uninudited) income (in thousands, consistent with consistent percentage consistent and consistent with consistent percentage)
Molecular Therapeutics, Inc. Condensed Balance Sheet Data (Unudited) (thousands)
Contacts:
Theresa Janketjanke@4dmt. com
Investors:
Mike Zanoni, Advisorsmzanoni@4dmt. com